Premium
SPIReL: PHASE 2 STUDY DPX‐SURVIVAC WITH INTERMITTENT LOW DOSE CYCLOPHOSPHAMIDE AND PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
Author(s) -
Berinstein N.L.,
BenceBuckler I.A.,
Laneuville P.,
Stewart D.,
Smyth L.,
Kerr C.,
Klein G.,
Pennell N.,
RoosAssar K.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.16_2632
Subject(s) - medicine , pembrolizumab , cyclophosphamide , oncology , survivin , chemotherapy , refractory (planetary science) , lymphoma , gastroenterology , cancer research , immunotherapy , cancer , biology , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom